Tests roxadustat against standard care in people on hemodialysis
Compares oral roxadustat with usual treatment for anemia and heart health in adults on dialysis.
Plain-language title generated from the registry record
Registry title: Roxadustat's Effect on Heart, Nutrition, and Inflammation in Hemodialysis Patients
Key facts
- Where
- Al Mansurah, EgyptSee the site
- Phase
- Phase 1/2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with end-stage kidney disease who have been on regular hemodialysis for more than 3 months. It compares Roxadustat with usual anemia treatment.
- Age
- More than 18 years old.
- Sex
- All sexes can join.
- Disease stage
- End-stage kidney disease on chronic hemodialysis for more than 3 months.
- Earlier treatment
- On hemodialysis for more than 3 months. The usual-treatment group continues its current anemia care.
Main reasons for not taking part
- Current pregnancy or breastfeeding
- Cancer that was already present
- Psychosis, or taking sleeping medicines (hypnotics)
- Blood disorders or other causes of anemia besides kidney disease or dialysis
- Severe heart and blood vessel disease
This trial only enrols participants on dialysis. The registry sentence this rests on: Patients with ESKD on chronic hemodialysis for more than 3 months.
Read by machine on 12 November 2026.
Where in Egypt
- Urology and Nephrology Center, Mansoura UniversityAl Mansurah, EgyptContact: Ibrahim M GalalahTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Mansoura University
- Trial code
- NCT06903559
- Record updated
- 13 May 2025
- Original description
Patients with kidney failure who require hemodialysis often suffer from anemia (low red blood cell count), heart and blood vessel problems, and a condition involving poor nutrition, inflammation, and hardening of the arteries (called MIA syndrome). Standard treatments for anemia often involve injections and iron supplements. This study aims to see if a newer oral medication, Roxadustat, works better than these standard treatments not only for anemia but also for improving cardiovascular health and the MIA syndrome.Read full original descriptionShow less
Effect of Roxadustat on Cardiovascular System and Malnutrition-Inflammation-Atherosclerosis (MIA) Syndrome in Hemodialysis Patients: A Randomized Controlled Study
Patients with kidney failure who require hemodialysis often suffer from anemia (low red blood cell count), heart and blood vessel problems, and a condition involving poor nutrition, inflammation, and hardening of the arteries (called MIA syndrome). Standard treatments for anemia often involve injections and iron supplements. This study aims to see if a newer oral medication, Roxadustat, works better than these standard treatments not only for anemia but also for improving cardiovascular health and the MIA syndrome.
Participants in the study will be randomly assigned (like by chance) to one of two groups. One group will receive Roxadustat, while the other group will continue with their conventional anemia treatment. Researchers will compare the effects on heart function, markers of nutrition and inflammation, and anemia levels in both groups over a 6-month period.
Inclusion: Age of patient is more than 18; Patients who are willing to sign informed consent; Patients with ESKD on chronic hemodialysis for more than 3 months.
Exclusion: Patients with pre-existing malignancy; Known history of hematological disorders or other known causes for anemia other than CKD or dialysis; Patients with severe cardiovascular disease; Current pregnancy or lactation; Patients with psychosis or on hypnotics; Refuse to participate in the study.